Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks.
It is likely not best to allocate monies to MDR TB for a company on the cusp of developing
Into a major player . CTIX needs to allocate finances where it would get the most bang for the buck.
That said, MDR TB from a public health perspective has the potential to cause a major very dangerous pandemic, hence hopefully soon research on defensin mimetic ANTI TB drugs could be considered.
That is IC90 less then 5 for TB, not talking about ABSSI
I meant IC90
3 of the compounds listed have ICD90 less then 5, not Brilicidin
See attached pmx presentation including compounds with anti-TB activity
https://www.dropbox.com/s/h8oz6ru2at7w9wv/AIDSSymposiumTBSept262008.pdf?dl=0
I predict news about Brilicidin -OM and Prurisol shortly after uplist. It is possibly the reason the trials have not officially started. Could there be a deal in the works?
One two punch : Potential ECCMID releases:B-OM ( BOOM) trial start, define Brilicidin data requested and released to FDA, Gm neg activity new Abx)
To get media attention to an uplist
1) Jabs:Have them intrigued about information released in conference
2) Knockout:Uplist on the same day
ASCO abstract titles are available next monday 4/20 via the i-planner, the actual abstract itself is not available until May.
http://am.asco.org/abstracts
STOCK POTENTIAL FOR LARGE GAIN IS SUBSTANTIAL IN NEAR FUTURE
1 )Uplist
2)European conference showcasing potential of defensin mimetic technology
3)Possible Antibiotic deal with major pharm
4)B-OM start
5)Info on purisol (did trial not start as deal is in works?)
6)Kevetrin update at ASCO
7)Other surprise from pipeline
Exhibitors pay to exhibit or showcase their product . Cellceutic is not an exhibitor, abstract presenters are not exhibitors.
Clinical Science Symposia
Clinical Science Symposia are offered throughout the Annual Meeting and provide a forum for science in oncology, combining the presentation of selected abstracts on a specific topic with didactic lectures by expert faculty. Speakers place the studies in the appropriate context based on the strength of the evidence and critically discuss the conclusions in terms of their applicability to clinical practice.
“I always like the Clinical Science Symposia because they provide an opportunity to understand pathways or molecules that might be effective across diseases. I’m convinced that the average oncologist really needs to understand more molecular biology than they ever used to,” Dr. Yee said.
The didactic lecture by an expert in the field to be given in the clinical science symposia may in fact be the presentation Cellceutix was asked to prepare
Perhaps we were selected for clinical science symposia see my last post regarding symposia and note cellceutix PR below:
Additionally, the Principal Investigators for the Kevetrin trial have requested that the Company start preparing a presentation to be used for an article on the safety and pharmacological effect of Kevetrin on multiple cancer lines as demonstrated in the clinical trial. Cellceutix interprets this recommendation as a very optimistic sign regarding anticipated outcomes for the trial and clinical advancement of Kevetrin.
All speakers participate in Q&A session see below from ASCO website
ORAL ABSTRACT SESSIONS
This type of session includes several 12-minute presentations of abstracts representing important clinical and translational research findings by topic category. Presenting authors may use SePowerPoint slides to accompany their oral presentation. Experts in the field (discussants) are chosen to provide comprehensive 12-minute themed discussions of the findings from predetermined abstracts. All speakers will participate in a question-and-answer panel in the session. The duration of this type of session is 3 hours. A limited number of abstracts deemed to represent the best science will be selected for presentation in the noncompeting plenary session.
CLINICAL SCIENCE SYMPOSIA
These sessions incorporate the presentation of meritorious abstracts with a didactic lecture by an expert who summarizes the field and places the abstracts in the appropriate context, with a focus on how the findings apply to clinical practice. Abstracts selected for these high-profile sessions may cross disease sites or disciplines but are unified in their focus on a key scientific topic as it relates to the field of cancer research
P21 changes are one of thesecondary outcome measures of the trial
Taken from clinicatrials.gov website
Changes in the biomarker p21 in peripheral blood lymphocytes [ Time Frame: baseline and 7 hours ] [ Designated as safety issue: No ]
For biomarker analysis, p21 expression, assayed by qPCR, in peripheral blood lymphocytes after Kevetrin administration.
Changes in the biomarker p21 in peripheral blood lymphocytes [ Time Frame: baseline and 24 hours ] [ Designated as safety issue: No ]
For biomarker analysis, p21 expression, assayed by qPCR, in peripheral blood lymphocytes after Kevetrin administration.
Regarding ASCO for trials in progress (from ASCO Website)
What is the abstract selection process for submitted Trials in Progress abstracts?
Abstracts will be reviewed by the ASCO Scientific Program Committee. Abstracts will be evaluated on
• STRENGTH OF THE SCIENCE underlying the trial
• NOVELTY of the study design and/or correlatives
• POTENTIAL FOR COLLABORATION
• Overall interest to the ASCO community
All phases of clinical research (phases I to III, supportive care, nonpharmacologic interventions) may be considered for inclusion in a Trials in Progress abstract submission. Trials submitted to this session are ongoing and have not reached prespecified endpoints for analysis. As such, inclusion of results would be improper and is strictly forbidden.
Possible reason for letter to shareholders without press release
Leo may just be giving current shareholders a leg up. This helps current shareholders by allowing us to purchase more shares before the BOOM that will come upon uplisting,which may also occur concurrently with other good news such as the start of B-OM ( the B-OM BOOM),possible presentation and release of data about p21 and tumor response at ASCO,release of final Bilradicin data at European infectious disease conf etc etc rtc...
Antiviral defensin properties
https://www.dropbox.com/s/wbkij9mx2ms0jsg/db_VD_Ebola_CPP-db_Defensins_Innate-Antiviral-Immunity.pdf?dl=0
Does anybody know if Polymedix or Cellceutix has worked on antiviral properties of defensin mimetic compounds?
ASCO ABSTRACT
The ASCO abstract submission deadline date is 2/3/15 @11:59 PM,late breaking abstract deadline is 4/1/15. There is thus a chance that we may get a PR in the next few days if an abstract about kevetrin will be presented .
Possible ASCO hint in last PR.....Could these particular words used in the last PR be a hint of a possible ASCO presentation?...... "preparing a presentation to be used for an article on the safety and pharmacological effect of Kevetrin on multiple cancer lines as demonstrated in the clinical trial."
With regards to ASCO and potential timing of release of data and info regarding kevetrin trial.
The ASCO abstract submission deadline is 2/3/15, ~3 weeks after the 1/12 meeting.The late breaking data submission deadline is 4/1/15. Abstract titles are released in late April and abstracts released on 5/13/15
Perhaps these dates will in part determine what if any kevetrin information will be released at the 1/12 meeting.
The stock recently has decreased share price because many believers in NNVC also have a position in the rapidly rising in price CT-- stock. These stockholders recently decided they needed to free up cash(hence selling NNVC) to add to their position in the other stock before further gains manifest. It is not that they changed their core positive beliefs about the NNVC platform,they just do not want to miss out on a potentially meteoric rise in the other stock. I believe NNVC will shortly also begin a climb in price once it announces Ebolacide progress. A shipment announcement would hopefully halt the decline. Favorable results may cause a gap up and I would not want to be out of NNVC at that time.
Article relevant to human proteome
https://www.dropbox.com/s/wgm1v21ooddlc0j/1559-0275-9-6-1.pdf?dl=0
Human B defensin in colon infectious and non infectious role
https://www.dropbox.com/s/gdbktvilbeov902/pathogens-02-00177.pdf?dl=0
Kevetrin causes cell cycle arrest at G2/M, making it likely a great radiation sensitizer
Please note below article on relationship between p53, cell cycle etc.
http://www.ncbi.nlm.nih.gov/pubmed/15234026
Please see my two earlier posts this AM together and post of ffrol in response to my first post for clarification about cystic fibrosis, high ionic salt environment and cystic fibrosis
https://www.dropbox.com/s/78rqwt775tk2r8m/ICAAC-poster-9-06-copy-low-1.pdf?dl=0
Polymedix compounds may work in high salt environment (see above poster) and hence be applicable to cystic fibrosis.
http://news.sciencemag.org/1997/02/crippled-antibiotic-linked-cystic-fibrosis-infections
This article is old but indicates a possible use for defensin antibiotics in cystic fibrosis
Likewise denguecide has been shown to have effect on cytokine
http://www.businesswire.com/news/home/20110222005851/en/NanoViricides-Presented-anti-Dengue-Hemorrhagic-Fever-Studies-Dengue#.VFxWmXMo7qA
Ebola kills via cytokine storm.
http://www.npr.org/blogs/goatsandsoda/2014/08/26/342451672/how-ebola-kills-you-its-not-the-virus
Flucide has been shown to protect against cytokine storm. PERHAPS SUCH ACTIVITY WILL AGAIN MANIFEST AND MAKE EBOLACIDE 2 a wonder drug
From: xcentral1 4/8/2011 12:38:55 PM
? of 2967
NanoViricides Reports FluCide(TM) Drug Candidates Found to Offer Significant Reduction in Damaging White Blood Cell Presence in Lung Tissue in Lethal Influenza Infection Animal Study
WEST HAVEN, Conn., Apr 07, 2011 (BUSINESS WIRE) -- NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide(TM) drug candidates resulted in significant reduction in lung tissue presence of leukocytes, and in particular, that of eosinophils in a lethal influenza infection animal model.
Four days post virus infection, animals treated with three of the optimized FluCide(TM) nanoviricide drug candidates exhibited a substantial reduction in overall leukocytes in lung tissue as compared to untreated infected control. More importantly, the eosinophil count in the lung tissues of the nanoviricide treated animals was also significantly lower than untreated animals. Further, this reduced lung tissue presence of damaging immune system cells was found to persist over the entire duration of study. In contrast, animals treated with Oseltamivir (Tamiflu(R), Roche) showed reduced eosinophil and leukocyte count initially that rapidly rose to the level of untreated animals.
Eosinophil expansion occurs in response to a viral infection, and is indicative of a viral infection. Various white blood cells (leukocytes) also increase in response to a viral infection. These phenomena are part of the normal immune response. In severe influenza cases, it is thought that patients can go into a stage called "cytokine storm syndrome". This may be thought of as an all-out attack by an expanded army of white blood cells in response to an uncontrolled viral infection. In an attempt to control the viral infection, the immune system attacks the infected cells as well as nearby normal cells. This can lead to severe lung damage that may rapidly become fatal.
"The finding that FluCide drug candidates showed substantially reduced extent of white blood cells, and in particular, eosinophils, in the lung tissue, is very significant," said Randall W. Barton, PhD Immunologist, CSO of the Company, adding, "This indicates that FluCide drug candidates may be highly effective in severe cases of influenza as well as cases of bird flu, H5N1, by protecting the patient from cytokine storm phenomena."
He also observed that the reduced white blood cell and eosinophil counts were consistent with the dramatic reduction in lung lesions that the Company has recently reported.
The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. The same quantity of virus infection was repeated at 22 hrs. This influenza model was designed to be uniformly fatal in 100% of the infected, untreated animals within 5 days after infection. Treatment with the FluCide candidates and Oseltamivir commenced 24 hours after the first viral infection. The duration of study was 21 days. Animals were sampled at 4.5, 9.5, 13.5 and 19.5 days for histological studies.
The Company had previously reported that the same three optimized FluCide(TM) nanoviricide drug candidates achieved significantly increased survival (20.2 to 22.2 days) as compared to animals treated with Oseltamivir (only 8.3 day survival). The lung histology (microscopic tissue examination) data show that the observed increase in survival was accompanied by a dramatic reduction in virus-induced lung inflammation and necrosis.
On 10/20 Lvus posted message from Seymour stating he was on 4 day trip looking at ways to dramatically increase production of Ebolacide2. On 10/30 the c ..x company announces s-3 shelf for 75 million, and one day later 10/31 Nnvc announces s3 for 50 million. Leo has relationships (present and past respectively with both companies)JUST SPECULATING .
http://www.nasdaq.com/press-release/rodman--renshaw-2014-annual-global-investment-conference-to-be-held-in-new-york-from-september-8-t-20140811-00275
Perhaps the market is reacting to this upcoming conference
Fireworks with the update or July 4th?
Per presentation at that time B - OM was planned to be a 60 pt Phase I I and 240 pt phase III (300 patients total) trial.
What is happening with arrayit pipeline prostate test?
http://www.onclive.com/publications/oncology-live/2014/may-2014/promising-biomarkers-emerging-across-the-spectrum-of-prostate-cancer-care/2
ASCO abstract 2014
http://abstracts.asco.org/144/AbstView_144_128776.html